Advanced Search

 

Study ID Status Title Patient Level Data
ADF30001 (Year 1 to Year 4) Completed A Multi-Center, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for the Treatment of ChinesePatients with HBeAg positive Chronic Hepatitis B Followed by Long-term (5 Years total) Adefovir Dipivoxil Treatment. (Report on data outto 4 years)
ADF30001_3 Completed A Multi-Center, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for theTreatment of Chinese Patients with HBeAg positive Chronic Hepatitis B Followed by Long-term (5 Years total)Adefovir Dipivoxil Treatment. (Report on interim data out to 3 years)
ADF30001_5 Completed A multicentre double blind randomised placebo controlled phase II/III study of adefovir dipivoxil for the treatment of Chinese patients with HBeAg positive chronic hepatitis B.
ADF30002 Completed Clinical Evaluation of Adefovir Dipivoxil [GW284873X] in Patients with chronic hepatitis B (including cirrhosis B) who have signs of clinical deterioration associated with the replication of YMDD variant HBV following lamivudine therapy
ADF30003 Completed Clinical evaluation of adefovir dipivoxil (GW284873X) in patients with chronic hepatitis B (including cirrhosis B) who have signs of clinical deterioration associated with the replication of YMDD variant HBV following lamivudine therapy – A follow-up long-term study of ADF30002 (a 16-week, open ...
ADG103440 Completed A randomised,double-blind, parallel group, placebo-controlled, multicentre study to evaluate the safety, tolerability and efficacy of oral GW677954 capsules 2.5mg, 5mg, 10mg and 20mg a day for 24 weeks in overweight dyslipidaemic subjects Study Listed on ClinicalStudyDataRequest.com
ADG20001 Completed A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
AK110016 Completed Final study report for a randomized, single-dose, three-way crossover study examining the bioequivalence of a reformulated WELLBUTRIN SR 100 mg tablet formulation versus the currently-marketed WELLBUTRIN SR 100 mg tablet formulation in healthy volunteers.
AK110021 Completed Single-Center, Randomized, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Safety of Multiple Fixed Doses of WELLBUTRIN SR (bupropion hydrochloride sustained release) Tablets in Outpatients with Untreated Stage I Hypertension Study Listed on ClinicalStudyDataRequest.com
AK110022 Completed An open-label, randomized, single-dose, two-way crossover study examining the bioequivalence of one newly formulated WELLBUTRIN SR† 200mg tablet versus two currently marketed WELLBUTRIN SR 100mg tablets in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
AK1102364 Completed An Open-Label, Multi-Cetre, Phase II Study Evaluating the Safety and Efficacy of 323U66 SR in Patients with Depression
AK1102365 Completed Clinical evaluation of 323U66 SR in patients with depression - Placebo-controlled, double-blind, comparative study in patients with depression who did not respond sufficiently to selective serotonin re-uptake inhibitors
AK1102369 Completed Clinical Evaluation of 323U66 SR in patients with Depression – Investigation in Elderly patients with Depression –
AK130926 Completed A Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450mg) and escitalopram (10-20mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period
AK130927 Completed A Multicenter, Double-blind Randomized Placebo-controlled Comparison of the Effects on Sexual Functioning of Extended-release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period
AK130930 Completed A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Phase
AK130931 Completed An 8 week, multicenter, randomized, double-blind, placebo controlled comparison of the efficacy of extended release bupropion hydrochloride and placebo in the treatment of adult outpatients with major depressive disorder with lethargic symptoms
AK130934 Completed An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder
AK130936 Completed A 7 Month, Multicenter, Randomized, Double-blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in subjects with a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase
AK130939 Completed A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder. Study Listed on ClinicalStudyDataRequest.com
AK130940 Completed A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-release Bupropion Hydrochloride (150mg-300mg once daily) in Elderly Subjects with Major Depressive Disorder
AK140016 Completed An eight-week double-blind study comparing the effects of 20 mg of paroxetine to 150 mg of Wellbutrin SR in patients with Major Depressive Disorder
AK1A1001 Completed A randomized, crossover study to evaluate the pharmacokinetic effect of cimetidine on WELLBUTRIN (Bupropion HCl) sustained release in healthy subjects.
AK1A1003 Completed An open-label, 30 day study to investigate the potential pharmacokinetic interaction of multiple doses (300mg/day) of WELLBUTRIN SR (bupropion hydrochloride) on single doses (50mg) of desipramine in normal volunteers designated extensive metabolizers via the CYP2D6 pathway.
AK1A4001 Completed A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCI) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.